Srdečně Vás zveme na přednášku pořádanou Biotechnologickým ústavem AV ČR, v. v. i., která se koná v pondělí 17. června 2019 od 15:00 v posluchárně Milana Haška, ÚMG, Krč.
Prof. Boris Turk, Ph.D., Jozef Stefan Institute, Ljubljana
"Extracellular cysteine cathepsin: Targets for diagnostics and therapy in cancer."
Inflammation plays an important role in disease onset and progression in a vast number of diseases, called also inflammation-associated diseases including various cancers, psoriasis, dermatitis, inflammatory bowel diseases, pancreatitis, various forms of arthritis, osteoarthritis, osteoporosis/bone resorption, septic shock, atherosclerosis, ischaemia-reperfusion injury, coronary heart disease, vasculitis, amyloidosis, pulmonary fibrosis, viral infections, systemic lupus erythematosus, and asthma. Proteases play a major role in a number of these diseases. However, understanding the precise role of an individual protease in a disease remains a major challenge for successful therapeutic applications. There are several ways how to address this issue, including the chemical biology approaches including small molecule inhibitors and activity-based probes, as well as by engineered macromolecules (e.g. DARPins). These approaches offer a major potential for noninvasive optical imaging by monitoring protease activities in situ, i.e. on disease site. Moreover, they enable also validation of proteases as drug targets, in vivo validation of drug candidates and evaluation of the diagnostic potential of the target proteases. Among the proteases found to be tightly linked with inflammation-associated diseases, including many types of cancer, are also cysteine cathepsins that can be found extracellularly at the sites of inflammation due to their secretion from primarily infiltrated immune cels, such as macrophages. Furthermore, since they are heavily upregulated in a number of inflammation-associated diseases, they are therefore perfect targets for such approaches. There is increasing evidence that monitoring cathepsin activity in vivo may be applicable to diagnostic imaging, such as demonstrated primarily for cancer. Moreover, cathepsins can be also used as targets for targeted drug delivery approaches combined with diagnostics, thereby offering a theranostic potential.